---
title: "Morgan Stanley raises the target price of Zhongsheng Pharmaceutical to 8.3 yuan, rating it as \"Overweight.\""
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282508730.md"
description: "Morgan Stanley published a research report, updating its risk-return assessment for SBP GROUP. The group's sales are expected to decline by 1%, 3%, and 3% respectively from 2026 to 2028. It is anticipated that the company's revenue will grow by 11% this year, benefiting from advance payments from Sanofi, as well as innovative drugs and biosimilars recording over 20% year-on-year growth, which is sufficient to offset the decline in the unit numbers of generic drugs. Morgan Stanley raised the group's target price from 8 yuan to 8.3 yuan, with a rating of \"Overweight.\""
datetime: "2026-04-13T07:58:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282508730.md)
  - [en](https://longbridge.com/en/news/282508730.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282508730.md)
---

# Morgan Stanley raises the target price of Zhongsheng Pharmaceutical to 8.3 yuan, rating it as "Overweight."

Morgan Stanley published a research report, updating the risk-return assessment for China National Pharmaceutical Group (01177.HK). It forecasts a decline in the group's sales of 1%, 3%, and 3% for the years 2026 to 2028, respectively. It expects the company's revenue to grow by 11% this year, benefiting from advance payments from Sanofi, as well as innovative drugs and biosimilars recording over 20% year-on-year growth, which is sufficient to offset the decline in generic drug unit numbers. Morgan Stanley raised the group's target price from HKD 8 to HKD 8.3, with a rating of "Overweight."

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)

## Related News & Research

- [Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate](https://longbridge.com/en/news/284532331.md)
- [ŌURA Closes the Hormonal Health Data Gap](https://longbridge.com/en/news/284975666.md)
- [ANALYSIS-Kone's new TK Elevator deal comes amid climate change on European champions](https://longbridge.com/en/news/285028789.md)
- [Metamucil Grabs the Mic: 90s Icons Lance Bass and Danielle Fishel Talk Fibermaxxing and Reveal the “OG Biohack” | PG Stock News](https://longbridge.com/en/news/285076844.md)
- [16:34 ETATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit](https://longbridge.com/en/news/284937772.md)